Histogen Inc (HSTO)
0.1501
-0.35
(-69.98%)
USD |
OTCM |
Apr 19, 15:32
Histogen Cash from Operations (TTM): -10.07M for Sept. 30, 2023
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
| Date | Value |
|---|---|
| September 30, 2023 | -10.07M |
| June 30, 2023 | -9.835M |
| March 31, 2023 | -11.89M |
| December 31, 2022 | -9.683M |
| September 30, 2022 | -9.962M |
| June 30, 2022 | -11.40M |
| Date | Value |
|---|---|
| March 31, 2022 | -11.26M |
| December 31, 2021 | -14.53M |
| September 30, 2021 | -15.89M |
| June 30, 2021 | -15.75M |
| March 31, 2021 | -14.76M |
| December 31, 2020 | -12.05M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (TTM) Range, Past 5 Years
-15.89M
Minimum
Sep 2021
-9.683M
Maximum
Dec 2022
-12.26M
Average
-11.64M
Median
Cash from Operations (TTM) Benchmarks
| CEL-SCI Corp | -23.07M |
| AIM ImmunoTech Inc | -21.27M |
| IGC Pharma Inc | -6.19M |
| NovaBay Pharmaceuticals Inc | -4.131M |
| Protalix BioTherapeutics Inc | -1.318M |